Clinical Trials Logo

Lung Injury, Acute clinical trials

View clinical trials related to Lung Injury, Acute.

Filter by:

NCT ID: NCT01114009 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Effects of Recruitment Maneuvers in Early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) Patients

Start date: March 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of lung recruitment maneuver in patients with early ALI/ARDS

NCT ID: NCT00996840 Completed - Lung Injury, Acute Clinical Trials

SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS

Start date: October 16, 2009
Phase: Phase 2
Study type: Interventional

This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre study for subjects with trauma (physical injury) who are at risk for developing Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). The primary purpose of the study is to evaluate the safety and tolerability of SB-681323, which is a potent, selective inhibitor of p38 alpha (MAPK) (prevents inflammation of tissue), in comparison to a placebo.

NCT ID: NCT00498251 Completed - Anesthesia Clinical Trials

Prevention of Lung Edema After Thoracic Surgery

Start date: September 2004
Phase: N/A
Study type: Interventional

Background : Acute lung injury (ALI) occasionally occurs after pulmonary resection and carries a bad prognosis with a high mortality rate ranging from 20 to 100%. Objectives : 1. to evaluate pre-, intra- and postoperative changes in hemodynamics, oxygenation indices as well as intra- and extravascular lung water using simple thermodilution technique and continuous arterial pressure analysis 2. to test the efficacy of inhaled beta2 -adrenergic agonist versus anticholinergic agents to reduce lung edema in patients undergoing thoracic surgery and in pigs subjected to lipolysacharide-induced ALI. Design of the research protocol: - Prospective controlled trial including surgical patients with high risk factors for ALI (n=60) allocated to receive inhaled drugs (randomised, double-blind, cross-over mode). - Main measurements: Intra-thoracic blood volume, intra- and extra-vascular lung water, hemodynamic parameters (CO, systolic arterial pressure/flow variations, dPmax, MAP, CVP), oxygenation indices (PaO2/FIO2), ventilatory parameters, clinical outcome data, histochemical and pathological data. Glossary CO = cardiac output; dPmax = maximal arterial pressure slope; SAP-V = systolic arterial pressure variations; Flow–V = Flow variations; MAP = mean arterial pressure; CVP = central venous pressure; PaO2=arterial oxygen pressure; FIO2= oxygen inspiratory fraction

NCT ID: NCT00141726 Completed - Clinical trials for Respiratory Distress Syndrome, Adult

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Start date: October 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant. This study will also examine the toxicity of treatment with etanercept as well as whether there is an improved quality of life in these patients.